Retirement Systems of Alabama Buys 239 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Retirement Systems of Alabama raised its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 0.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 129,611 shares of the biotechnology company’s stock after purchasing an additional 239 shares during the quarter. Retirement Systems of Alabama’s holdings in United Therapeutics were worth $45,732,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the business. Creative Planning grew its position in United Therapeutics by 20.1% during the second quarter. Creative Planning now owns 3,613 shares of the biotechnology company’s stock valued at $1,151,000 after buying an additional 605 shares during the period. B. Riley Wealth Advisors Inc. grew its position in shares of United Therapeutics by 10.2% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 1,067 shares of the biotechnology company’s stock valued at $340,000 after acquiring an additional 99 shares during the period. Cetera Investment Advisers increased its stake in shares of United Therapeutics by 8.7% during the 2nd quarter. Cetera Investment Advisers now owns 6,167 shares of the biotechnology company’s stock worth $1,964,000 after purchasing an additional 493 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of United Therapeutics by 66.1% in the 3rd quarter. SG Americas Securities LLC now owns 1,493 shares of the biotechnology company’s stock worth $535,000 after purchasing an additional 594 shares during the period. Finally, Park Avenue Securities LLC lifted its stake in United Therapeutics by 8.3% in the third quarter. Park Avenue Securities LLC now owns 2,207 shares of the biotechnology company’s stock valued at $791,000 after purchasing an additional 170 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $353.64, for a total value of $3,536,400.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $911,330.28. This represents a 79.51 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Judy D. Olian sold 1,750 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $412.48, for a total value of $721,840.00. Following the completion of the transaction, the director now owns 5,655 shares of the company’s stock, valued at $2,332,574.40. The trade was a 23.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 143,838 shares of company stock worth $53,981,956 over the last ninety days. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $353.43 on Wednesday. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $417.82. The business’s fifty day moving average is $364.28 and its 200 day moving average is $357.68. The firm has a market cap of $15.78 billion, a price-to-earnings ratio of 15.52, a PEG ratio of 0.92 and a beta of 0.57.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on UTHR. UBS Group raised their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. TD Cowen boosted their target price on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Argus boosted their target price on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Oppenheimer boosted their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Finally, The Goldman Sachs Group boosted their target price on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $378.36.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.